Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Hempdocon Jun 28, 2020 2:37pm

237 Views

Post# 31200684

RE:RE:RE:RE:RE:New Paper on TLD-1433 and Lung Cancer

Eoganacht wrote: Hi Hempdoc - This is from the June 20, 2016 press release

"...Under worldwide exclusive licence agreement with the inventor of the latest patent, Dr. Sherri McFarland has agreed to maintain strict confidentiality on any trade secrets associated with the synthesis or manufacture of TLD-1433 for a period of twenty (20) additional years following the expiry of the last patent covering inventions or improvements in compounds or their methods of use; thereby, increasing minimum proprietary protection of TLD-1433 in the US until June 22, 2054..."

Thanks Eoganacht...considering Theralase is an exclusive licensee, how is Sherri able to share our compound/trade secret with another company, unless we modified the agreement. What am I missing?

Hempdoc wrote:

fredgoodwinson wrote: Interesting also to note that they used the Full Monte but from memory this is open source.

Seems that Sherri has taken TLD-1433 elsewhere.

What does this all mean? - and if price sensitive (as it almost certainly is) shouldn`t we have been told?

Nice find by Eog...Question for some of you longer longs...So I guess TLT does not have an exclusivity agreement to use/sell TLD-1433 for cancers other than NMIBC? Doesn't our patent cover other indications?